Please login to the form below

Not currently logged in

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover

Obagi treatments

Merz Pharma has elected not to raise its $385m offer for dermatology specialist Obagi Medical Products, clearing the way for a takeover by rival Valeant Pharmaceuticals.

Merz made an offer for Obagi last week that trumped an earlier $360m offer from Valeant but bowed out of the bidding after Valeant came back to the table with a $24-per-share offer that valued the business at around $418m.

"Obagi was an opportunity worth pursuing given its complementary fit," said Merz chief executive Philip Burchard in a statement.

"However, Merz is a disciplined buyer and at this level the economics of such a transaction do not meet our requirements," he added, noting that Merz will be exploring other acquisition opportunities.

Obagi's management seemed to favour a merger with Valeant, and the withdrawal of Merz now sets the clock ticking on Valeant's bid which expires on April 23 and is conditional on a majority of Obagi shares being tendered by the midnight deadline.

Analysts have suggested that it is unlikely any other buyers will emerge at this late stage.

The offer for Obagi comes after a string of acquisitions by Valeant in the dermatology sector. Last year, it bought skincare specialist Medicis in a $2.6bn deal that added Botox rival Dysport (abobotulinumtoxin A) to its portfolio along with a range of wrinkle treatments. This was after earlier deals for Johnson & Johnson's Ortho Dermatologics and Sanofi's Dermik skincare business.

Obagi would add products such as the Nu-Derm range of moisturisers and prescription products distributed through dermatology and plastic surgery clinics for conditions such as premature aging, photodamage, hyperpigmentation, acne, sun damage and facial redness.

9th April 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...